First Patient Enrolled In SeaStar Medical's Pivotal Clinical Trial With The Selective Cytopheretic Device In Adults With Acute Kidney Injury
Portfolio Pulse from Happy Mohamed
SeaStar Medical has enrolled its first patient in the NEUTRALIZE-AKI pivotal clinical trial to evaluate the safety and efficacy of its Selective Cytopheretic Device (SCD) extracorporeal therapy in adults with acute kidney injury (AKI) requiring continuous kidney replacement therapy (CKRT). The trial follows the resolution of a supply-chain issue.
June 20, 2023 | 8:08 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
SeaStar Medical begins enrollment in its NEUTRALIZE-AKI clinical trial for its Selective Cytopheretic Device, potentially benefiting over 200,000 U.S. adult patients with AKI.
The enrollment of the first patient in the NEUTRALIZE-AKI clinical trial is a significant milestone for SeaStar Medical. The successful resolution of the supply-chain issue and the potential to benefit over 200,000 U.S. adult patients with AKI requiring CKRT indicate a positive short-term impact on the company's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100